Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Eukaryotic translation initiation factor 2 subunit gamma (EIF2S3) is the largest subunit of the eIF2 complex, a heterotrimeric GTP-binding protein essential in the early steps of eukaryotic protein synthesis. It facilitates the recruitment of the initiator methionyl-tRNA and GTP to the 40S ribosomal subunit, forming the ternary complex, and helps assemble the 43S pre-initiation complex. Perturbations in EIF2S3 function are linked to human diseases such as MEHMO syndrome and neonatal diabetes mellitus, highlighting its role in translation control and cellular homeostasis[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Eukaryotic translation initiation factor 2 subunit gamma (EIF2S3).